The short answer: yes, for what it's approved to do
Ozempic works, and the clearest evidence is for the uses it is actually FDA-approved for. According to the current FDA prescribing information (2025), Ozempic (semaglutide) injection is indicated to improve blood-sugar control in adults with type 2 diabetes, to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of worsening kidney function, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
Notice what is not on that list: weight loss. Ozempic itself is not FDA-approved as a weight-loss drug. The same molecule, semaglutide, is approved for chronic weight management under a different brand name, Wegovy, at higher doses. When people ask 'does Ozempic work for weight loss,' they are usually really asking whether semaglutide works, and the trial answer is yes, but the studies that prove it used the weight-management dose. Prescribing Ozempic specifically to lose weight is an off-label use, a decision only a licensed clinician can make.
This distinction matters for anyone reading reviews online, because the dramatic before-and-after stories usually reflect the higher weight-management dose, longer treatment time, or both.
How well it works for type 2 diabetes (the SUSTAIN trials)
For blood-sugar control, the evidence is strong and consistent. The SUSTAIN 1-7 program tested semaglutide against placebo and against other diabetes drugs. Across SUSTAIN 1-5 and 7, average A1C (a 3-month blood-sugar marker) fell by roughly 1.2-1.5 percentage points on the 0.5 mg dose and 1.5-1.8 percentage points on the 1 mg dose, compared with almost no change on placebo (Aroda et al., Diabetes & Metabolism, 2019).
In a head-to-head trial (SUSTAIN 7), semaglutide 1 mg beat dulaglutide 1.5 mg, cutting A1C by 1.8 versus 1.4 percentage points and producing more weight loss (Pratley et al., Lancet Diabetes & Endocrinology, 2018). For context, a 1.5-point A1C drop is a large, clinically meaningful improvement in diabetes management.
Beyond blood sugar, SUSTAIN 6 was the cardiovascular outcomes trial that supports the heart-risk indication, and the FLOW kidney trial supports the newer chronic-kidney-disease indication now listed on the label. These are the pillars of why the drug is prescribed for diabetes in the first place.
How well semaglutide works for weight loss (STEP 1)
The landmark weight-loss evidence comes from STEP 1 (Wilding et al., New England Journal of Medicine, 2021), which tested once-weekly semaglutide 2.4 mg, the Wegovy dose, in 1,961 adults with overweight or obesity but without diabetes, over 68 weeks, alongside lifestyle counseling.
Average weight change was -14.9% with semaglutide versus -2.4% with placebo, about 15% of total body weight, or roughly 33 pounds for a 220-pound person. The response distribution is the more useful number: 86.4% of participants lost at least 5% of their body weight, 69.1% lost at least 10%, and 50.5% lost at least 15%. Those are strong odds compared with older weight-loss drugs.
But averages hide variation. A meaningful minority lost less than 5%, and results in the real world tend to be smaller than in a tightly monitored trial with built-in lifestyle support. 'It works' does not mean 'it works the same for everyone,' which is why an individual assessment by a clinician matters more than the headline percentage.
The part reviews skip: it works only while you keep taking it
This is the single most important honesty point about Ozempic and semaglutide, and it is missing from most glowing reviews. These medications treat the underlying biology of appetite and metabolism; they do not permanently reset it. When treatment stops, the biology reasserts itself.
In the STEP 1 trial extension (Wilding et al., Diabetes, Obesity & Metabolism, 2022), participants were followed for a year after stopping. They regained about two-thirds of the weight they had lost, and blood pressure and other cardiometabolic markers drifted back toward their starting points. Observed weight loss went from about 17.3% at week 68 to a net 5.6% below baseline at week 120.
The mirror-image trial, STEP 4 (Rubino et al., JAMA, 2021), showed the flip side: people who kept taking semaglutide after a 20-week run-in lost another 7.9% on average, while those switched to placebo gained back 6.9%. The takeaway from the trials themselves is that obesity behaves like a chronic condition, and semaglutide is a long-term management tool rather than a short course. Whether, how long, and how to stop are decisions for a prescribing clinician, not something to self-manage.
Real-world reviews vs. trial results: the adherence gap
Search 'Ozempic reviews' and you'll find both miracle stories and disappointment. Much of that gap comes down to who keeps taking it, and for how long. In clinical trials, people are screened, supported, and closely followed. In real life, many stop early.
A large U.S. cohort study of 125,474 adults (Rodriguez et al., JAMA Network Open, 2025) found that within one year, 46.5% of people with type 2 diabetes and 64.8% of those without diabetes had discontinued their GLP-1 medication; by two years, 71.9% overall had stopped. A separate analysis (JAMA Network Open, 2024) found roughly 37% discontinued within 12 months. The most common documented reasons were side effects, most often gastrointestinal like nausea, and cost.
Because the drug works only while taken, early discontinuation is a major reason real-world results underperform the trials. People who lost more weight and had fewer side effects were more likely to stay on treatment, which partly explains the wide range of experiences in reviews.
Who it works less well for, and why
Even taken consistently, semaglutide does not produce the same result for everyone. In STEP 1, roughly one in seven participants did not reach 5% weight loss, a group sometimes described informally as 'non-responders.' Response can be lower for people who stop early because of side effects, and the drug is not a substitute for the everyday inputs it works alongside.
It is also not appropriate for everyone. The FDA label carries a boxed warning about thyroid C-cell tumors seen in rodent studies and lists contraindications including a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Eligibility, screening, and monitoring are clinical decisions.
The practical point: 'does Ozempic work' has no universal answer. It works well on average for its approved uses, less predictably for any given individual, and never in isolation from the rest of a treatment plan.
A tool, not magic: it works with diet and activity
Every trial cited here paired semaglutide with lifestyle intervention, including dietary counseling and physical activity. The medication was never tested as a standalone fix, and it was not designed to be one. It reduces appetite and helps regulate blood sugar, which makes eating patterns easier to change, but the change still has to happen.
Framed honestly, semaglutide lowers the difficulty of the behaviors that drive weight and metabolic health; it does not remove them. That framing also explains the regain data: when the pharmacological help is withdrawn, the underlying drivers return unless other supports are in place.
If you're weighing whether a GLP-1 medication fits your goals, the productive next step is a conversation with a licensed provider who can review your history, screen for contraindications, and set realistic expectations. Compare vetted GLP-1 telehealth options below, and use them to reach a clinician, not to self-prescribe.